Novartis finally delivers gene therapy data in older SMA patients. Will they still want it? Since Zolgensma’s approval for babies with spinal muscular atrophy, other treatments have hit the market

https://www.statnews.com/2025/03/19/spinal-muscular-atrophy-novartis-zolgensma-older-children/